TCR mimic Antibody

Advantages of Biocytogen's TCR mimic Antibody Platform

• Biocytogen's unique HLA/RenMab mice, combined with our high-throughput antibody screening platform, enables a one-step process to generate fully human antibodies in vivo that identify human MAPs with high affinity.
• The antibodies selected through screening have better affinity and specificity than TCRs.
• The in situ large-fragment replacement and modification in RenMab mice ensures the diversity of antibody sequences.
• Our discovery process involves high-throughput screening in shortened timelines using the Beacon Optofluidic System and subsequent sequencing.
• The fully antibody sequences obtained by the TCR mimic antibody technology platform provide more candidates for subsequent antibody-related drugs, CAR-T, TCR-T and other fields. It provides more intracellular targets for targeted clearance of specific abnormal cells such as tumor cells, infected cells and senescent cells. In addition, TCR-like blocking antibodies can also be utilized to spare cell populations that are attacked by autoimmune disease, so as to avoid damage to normal tissues.

Biocytogen's RenTCRmimic-based TCR mimic Antibody Platform

TCR mimic Antibody developed from RenTCRmimic mice

Biocytogen's Fully Human TCRm Antibody Discovery Workflow

Most traditional antibodies target cell surface antigens (PD-1 and PD-L1, etc) or soluble antigens. However, ideal tumor antigens are often intracellular, (RAS, P53, WT1, etc). Endogenous T cell receptor (TCR) can recognize intracellular antigen/HLA complex, i.e. MHC-antigen-peptide, MAP, to activate T cells against tumor cells. But their affinity to the antigen is low, which often leads to tumor immune escape.

Biocytogen's TCR mimic (TCRm) antibody technology platform is designed for the discovery of TCRm antibodies with high affinity and specificity compared with endogenous TCRs.

Biocytogen's TCR mimic Antibodies under Development